Patent 7700593 was granted and assigned to Amgen on April, 2010 by the United States Patent and Trademark Office.
The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I